Atea Pharma Issues New 164.8K Share Option to Director Howard Berman

Rhea-AI Filing Summary

A Form 4 filed for Atea Pharmaceuticals, Inc. (AVIR) discloses that director Howard Berman received a new equity incentive award on 20 June 2025. The filing reports the grant of a stock option to purchase 164,800 shares of common stock at an exercise price of $3.25 per share. The option vests in 36 equal monthly installments beginning on the grant date and will be fully vested on 20 June 2028. It carries an expiration date of 19 June 2035. No acquisitions or dispositions of common shares were reported in Table I; the entire award is recorded in Table II as a derivative security held directly (Form D ownership). Following the grant, Berman’s reported beneficial ownership consists of 164,800 derivative securities tied to common stock. The transaction is coded “A,” indicating an award rather than a market purchase or sale.

Insights

Securities Analyst

TL;DR: Routine option grant aligns director incentives; limited immediate market impact.

The Form 4 records a standard incentive option issuance to director Howard Berman. With 164,800 shares underlying and a $3.25 strike price, the award represents future—not current—ownership dilution of roughly this amount, subject to vesting through mid-2028. Such grants are typical for board compensation and signal continued tenure but do not change cash flows, earnings, or near-term share count. The 10-year term (to 2035) is standard. Overall, the filing is informational and neutral for valuation unless compounded by many similar grants.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Berman Howard

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	164,800	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 164,800 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berman Howard

(Last) (First) (Middle)

225 FRANKLIN STREET SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.25	06/20/2025		A		164,800		(1)	06/19/2035	Common Stock	164,800	$0	164,800	D

Explanation of Responses:

1. The option vests and becomes exercisable in thirty-six (36) equal monthly installments following June 20, 2025 such that the option is fully vested on June 20, 2028.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Howard Berman	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.